Healthcare & Medical Devices Global On demand · 24-48h

Global HER2 Tumor Marker Testing Market Strategic Research Report

Global HER2 Tumor Marker Testing Market Strategic Research R…
$3,500 USD
Market Research Reports
Strategic Research Report
Global HER2 Tumor Marker Testing Market
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH), Silver In Situ Hybridization (SISH), Others

By Application: Hospitals, Diagnostic Laboratories, Others

Key Players: Abbott, Roche, Thermo Fisher Scientific, Agilent, Leica Biosystems, Biocare Medical, BioGenex, Sysmex, Abnova, Novartis, InvivoGen

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2024 · forecast to 2032
Length: 105 pages

Overzicht

Scope of the Report

HER2 Tumor Marker Testing is a diagnostic test used in oncology to assess the status of the HER2 gene and the presence of HER2 protein receptors in breast cancer and some other types of cancer, such as gastric (stomach) cancer. HER2 stands for Human Epidermal Growth Factor Receptor 2, which is a gene that encodes a protein receptor on the surface of certain cells, including breast cells. HER2 status is an important factor in determining treatment options and predicting the prognosis for individuals with specific types of cancer.

The global market for HER2 Tumor Marker Testing has been experiencing steady growth. This growth is primarily driven by the increasing incidence of breast cancer and the importance of HER2 status in determining treatment decisions. The market size is influenced by factors such as population aging, awareness of breast cancer screening, and advancements in diagnostic techniques. North America, particularly the United States, is a significant market for HER2 Tumor Marker Testing. The region has well-established breast cancer screening and diagnosis programs. The adoption of targeted therapies, such as Herceptin, has been prominent in this region. Europe also has a substantial market for HER2 testing, with countries like the United Kingdom, Germany, and France being key contributors. The European market is characterized by a growing emphasis on early cancer detection and personalized medicine. The Asia-Pacific region, including countries like China and India, offers growth opportunities. The increasing healthcare spending, growing awareness of breast cancer, and rising population contribute to market expansion.

This report presents a comprehensive overview of the global HER2 Tumor Marker Testing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

Segment by Application

  • Hospitals
  • Diagnostic Laboratories
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global HER2 Tumor Marker Testing market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospitals, Diagnostic Laboratories, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Segments covered in this report

By Type
Immunohistochemistry (IHC)Fluorescence In Situ Hybridization (FISH)Silver In Situ Hybridization (SISH)Others
By Application
HospitalsDiagnostic LaboratoriesOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Immunohistochemistry (IHC)
  • 3.1.3 Fluorescence In Situ Hybridization (FISH)
  • 3.1.4 Silver In Situ Hybridization (SISH)
  • 3.1.5 Others
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospitals
  • 4.1.3 Diagnostic Laboratories
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Abbott
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Roche
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Thermo Fisher Scientific
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Agilent
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Leica Biosystems
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Biocare Medical
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 BioGenex
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Sysmex
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Abnova
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Novartis
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 InvivoGen
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is HER2 Tumor Marker Testing?
HER2 Tumor Marker Testing is a diagnostic test used in oncology to assess the status of the HER2 gene and the presence of HER2 protein receptors in breast cancer and some other types of cancer, such as gastric (stomach) cancer. HER2 stands for Human Epidermal Growth Factor Receptor 2, which is a gene that encodes a protein receptor on the surface of certain cells, including breast cells. HER2 status is an important factor in determining treatment options and predicting the prognosis for individuals with specific types of cancer.
How is the HER2 Tumor Marker Testing market segmented by type?
By type, the market is segmented into Immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH), Silver In Situ Hybridization (SISH) and Others.
What are the key applications of HER2 Tumor Marker Testing?
Key applications covered include Hospitals, Diagnostic Laboratories and Others.
Which companies are profiled in the HER2 Tumor Marker Testing market report?
Key players profiled include Abbott, Roche, Thermo Fisher Scientific, Agilent, Leica Biosystems, Biocare Medical, BioGenex and Sysmex, among 11 companies covered in total.
What geographies does the HER2 Tumor Marker Testing market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for HER2 Tumor Marker Testing?
This growth is primarily driven by the increasing incidence of breast cancer and the importance of HER2 status in determining treatment decisions.
Who should buy the HER2 Tumor Marker Testing market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospitals, Diagnostic Laboratories and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the HER2 Tumor Marker Testing market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$ 3.500,00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.